Shorter regimens for multidrug-resistant tuberculosis should also be applicable in Europe
نویسندگان
چکیده
منابع مشابه
Should treatment of multidrug resistant tuberculosis be individualised ?
T e a r t i c l e t i t l e d “ S u c c e s s f u l management of highly drug resistant Tuberculosis with individualized drug susceptibility testing” in this issue of the Journal deserves special attention. It brings forth an important issue of fallacies and benefits of TB treatment offered by private practitioners versus treatment offered by publ ic sector physicians under the revised national...
متن کاملMultidrug-Resistant Tuberculosis in Europe, 2010–2011
Drug-resistant Mycobacterium tuberculosis is challenging elimination of tuberculosis (TB). We evaluated risk factors for TB and levels of second-line drug resistance in M. tuberculosis in patients in Europe with multidrug-resistant (MDR) TB. A total of 380 patients with MDR TB and 376 patients with non-MDR TB were enrolled at 23 centers in 16 countries in Europe during 2010-2011. A total of 52....
متن کاملShorter treatment duration for selected patients with multidrug-resistant tuberculosis.
Opinion and Marketing Research. ICC/ESOMAR International Code On Market and Social Research www.esomar.org/index. php/codes-guidelines.html Date last updated: December 2007. 6 Heck JE, Stücker I, Allwright S, et al. Home and workplace smoking bans in Italy, Ireland, Sweden, France and the Czech Republic. Eur Respir J 2010; 35: 969–979. 7 Winickoff JP, Gottlieb M, Mello MM. Regulation of smoking...
متن کاملPrinciples for designing future regimens for multidrug-resistant tuberculosis.
Fewer than 20% of patients with multidrug-resistant (MDR) tuberculosis are receiving treatment and there is an urgent need to scale up treatment programmes. One of the biggest barriers to scale-up is the treatment regimen, which is lengthy, complex, ineffective, poorly tolerated and expensive. For the first time in over 50 years, new drugs have been developed specifically to treat tuberculosis,...
متن کاملAggressive regimens for multidrug-resistant tuberculosis reduce recurrence.
BACKGROUND Recurrent tuberculosis disease occurs within 2 years in as few as 1% and as many as 29% of individuals successfully treated for multidrug-resistant (MDR) tuberculosis. A better understanding of treatment-related factors associated with an elevated risk of recurrent tuberculosis after cure is urgently needed to optimize MDR tuberculosis therapy. METHODS We conducted a retrospective ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Respiratory Journal
سال: 2017
ISSN: 0903-1936,1399-3003
DOI: 10.1183/13993003.00463-2017